Neurocrine Biosciences director proposes $2.48M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neurocrine Biosciences Inc. (NBIX) director Gary A. Lyons reported a proposed sale of 15,000 common shares for the account of Gary A. Lyons Revocable Living U/A dated June 8, 2012. The notice gives an approximate sale date of November 17, 2026, and an aggregate market value of $2,479,650.00. The shares were acquired from the issuer through a cash-paid stock-option exercise on November 17, 2026. The notice lists August 18, 2026 as the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for the NBIX proposed sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.